We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lateral Flow Assay Enhanced for Multiplex Detection

By LabMedica International staff writers
Posted on 20 Mar 2013
Lateral flow assays (LFAs) are popular point-of-care diagnostic tools because they are rapid and easy to use. More...
However, LFAs often lack analytical sensitivity and quantitative output and may be difficult to multiplex, limiting their usefulness in biomarker measurement.

Scientists at SRI International (Menlo Park, CA, USA) designed a quantitative, multiplex LFA with readily available near-infrared (NIR) detection to improve analytical sensitivity. They constructed and optimized a multiplex LFA that simultaneously and accurately measured interleukin (IL)-6 and C- reactive protein (CRP) in 10% human plasma on one test strip.


Commercially available antibodies were conjugated with the fluorescent dye IRDye 800CW (Li-Cor; Lincoln, NE, USA). The investigators used singleplex, optimized NIR-LFAs to measure IL-6 from 0 to 200 pg/mL and developed duplex assays to simultaneously measure IL-6 from 0 to 100 pg/mL (0 to 4.5 pmol/L) and CRP from 50 to 2,500 ng/mL (0.4 to 20 nmol/L) on a single test strip. Assays were tested on 60 different spiked samples and compared to enzyme-linked immunosorbent assay (ELISA) results. The intensity ratios for unknown samples were compared to the calibration curve to determine analyte concentrations and samples were run in quadruplicate.

The choice of an inhibition-style assay rather than a sandwich-style assay avoided the complications due to a potential hook effect at high CRP concentrations. With this approach, free CRP present in the sample inhibited binding of the dye-conjugated antibody to CRP striped on the membrane. As the concentration of CRP in the sample increases, the signal directly decreases. The NIR-LFAs detected IL-6 in a 10% plasma matrix with a limit of detection of 4 pg/mL (182 fmol/L). The duplex NIR-LFAs quantitatively measured IL-6 and CRP concentrations simultaneously. The values strongly correlated to ELISA measurements, with linear regression R2 values of 0.9825 and 0.9711 for IL-6 and CRP, respectively.

The authors concluded that NIR-LFAs exhibit quantitative measurement at pg/mL concentrations owing to a high signal-to-background ratio and robust detection antibody clearance through the test strip. Moreover, NIR-LFAs are able to detect molecules present at vastly different concentrations in multiplex format and compare favorably to ELISAs. LFAs with direct NIR detection may be a valuable tool for biomarker evaluation in the point-of-care setting. The study was published on January 30, 2013, in the journal Clinical Chemistry.

Related Links:
SRI International
Li-Cor



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.